This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.
Valid: February 11th, 2010 - February 11th, 2011
This continuing medical education program is designed for medical professionals with an interest in oncology and the complications associated with metastasis to the skeleton.
At the completion of this activity participants should be able to:
- Explain the impact of skeletal-related events (SREs) associated with cancer and cancer related treatments, with an emphasis on multiple myeloma (MM)
- Review best practices for managing patients with skeletal complications based on key clinical evidence, appropriate practice guidelines, and patient case studies
- Discuss the role of bisphosphonates in treating bone loss associated with bone metastases based on findings from recent clinical trials evaluating the safety and efficacy of these agents
- Review the role of emerging treatments that may benefit patients who experience bone loss and pain associated with bone metastases
Estimated time to complete this activity: 1.0 hour
Physician Credit Designation
The University of Cincinnati designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.0 contact hour.
Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.0 contact hour (0.1 CEU) of continuing education credit. The universal program number for this activity is 0468-9999-10-052-H01-P.
Before the activity, all faculty disclosed the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial product(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakerâ€™s bureau membership, stock ownership, or other special relationships.
The University of Cincinnati, the associates of MLI, the accredited provider for this activity, and Coalition of Bone Health Educators, do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity for any amount during the past 12 months.
There is no discussion of non-FDAâ€“approved or investigational use of any product/device.
G. David Roodman, MD, PhD, discloses that he is a consultant for Amgen, Millennium, Celgene, Acceleron, and Novartis. He is also on the speaker's bureau for and receives research support from Novartis.
John D. Shaughnessy, Jr, PhD, discloses that he is an advisor for Myelogix, Genzyme, Novartis, and Celgene.
Noopur Raje, MD, discloses that she is a consultant for Celgene, Novartis, Amgen, and Millennium.
*Content will include non-FDA-approved uses.
The information provided in this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.
Trade names used in this supplement are for the learner's reference only. No promotion of or bias toward any product should be inferred.